FILTER
FILTERED INTERVIEW RESULTS
Peter DeYoung
CEO, PIRAMAL PHARMA SOLUTIONS
Piramal Pharma Solutions comments on its continued global expansion.
Manni Kantipudi & Ramesh Subramanian
CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF COMMERCIAL OFFICER (CCO), ARAGEN LIFE SCIENCES
Aragen Life Sciences explains how its expansion in both India and US can benefit drug discovery companies.
Robert Bloder
CHIEF BUSINESS OFFICER, ASCENDIA PHARMACEUTICALS
"We were excited to secure equity investment from Signet Healthcare Partners and have since almost doubled in size in both our capacity and talent pool."
Will Lewis
CHAIRMAN & CEO, INSMED
"Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection."
Anne Pritchett
SENIOR VICE PRESIDENT OF POLICY, RESEARCH AND MEMBERSHIP, PHRMA
"Our organization advocates for public policies that encourage the research and development and manufacturing of new medicines that allow patients to lead longer, healthier, and more productive lives."
Tom Sellig
CEO, ADARE PHARMA SOLUTIONS
"Our reputation is based on how we deploy technologies to solve complex formulation challenges."
Mark Jara
PRINCIPAL AND MANAGING DIRECTOR, RXS
"Tele-health tactics gained momentum and our clients made their pivot, like other industries, to fully remote operations. RxS, with our technology-forward approach, was prepared for the shift."
Candice Long
PRESIDENT – US INFECTIOUS DISEASES & VACCINES, JANSSEN PHARMACEUTICALS
"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."
Joe Panetta
PRESIDENT & CEO, BIOCOM CALIFORNIA
"We experienced explosive growth across the state and consequently adopted a new name: Biocom California."
John Pennett
PARTNER-IN-CHARGE OF THE NATIONAL TECHNOLOGY AND LIFE SCIENCES GROUP, EISNERAMPER
EisnerAmper speaks about the investment climate for pharma entrepreneurs.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
